Literature DB >> 29915065

Timing of DNA damage responses impacts persistence to fluoroquinolones.

Wendy W K Mok1, Mark P Brynildsen2.   

Abstract

Bacterial persisters are subpopulations of phenotypic variants in isogenic cultures that can survive lethal doses of antibiotics. Their tolerances are often attributed to reduced activities of antibiotic targets, which limit corruption and damage in persisters compared with bacteria that die from treatment. However, that model does not hold for nongrowing populations treated with ofloxacin, a fluoroquinolone, where antibiotic-induced damage is comparable between cells that live and those that die. To understand how those persisters achieve this feat, we employed a genetic system that uses orthogonal control of MazF and MazE, a toxin and its cognate antitoxin, to generate model persisters that are uniformly tolerant to ofloxacin. Despite this complete tolerance, MazF model persisters required the same DNA repair machinery (RecA, RecB, and SOS induction) to survive ofloxacin treatment as their nongrowing, WT counterparts and exhibited similar indicators of DNA damage from treatment. Further investigation revealed that, following treatment, the timing of DNA repair was critical to MazF persister survival because, when repair was delayed until after growth and DNA synthesis resumed, survival was compromised. In addition, we found that, with nongrowing, WT planktonic and biofilm populations, stalling the resumption of growth and DNA synthesis after the conclusion of fluoroquinolone treatment with a prevalent type of stress at infection sites (nutrient limitation) led to near complete survival. These findings illustrate that the timing of events, such as DNA repair, following fluoroquinolone treatment is important to persister survival and provide further evidence that knowledge of the postantibiotic recovery period is critical to understanding persistence phenotypes.

Entities:  

Keywords:  DNA damage; MazF; SOS response; persistence; starvation

Mesh:

Substances:

Year:  2018        PMID: 29915065      PMCID: PMC6142227          DOI: 10.1073/pnas.1804218115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  59 in total

Review 1.  Heterogeneous bacterial persisters and engineering approaches to eliminate them.

Authors:  Kyle R Allison; Mark P Brynildsen; James J Collins
Journal:  Curr Opin Microbiol       Date:  2011-09-19       Impact factor: 7.934

2.  Bacterial persistence as a phenotypic switch.

Authors:  Nathalie Q Balaban; Jack Merrin; Remy Chait; Lukasz Kowalik; Stanislas Leibler
Journal:  Science       Date:  2004-08-12       Impact factor: 47.728

Review 3.  Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies.

Authors:  Maarten Fauvart; Valerie N De Groote; Jan Michiels
Journal:  J Med Microbiol       Date:  2011-04-01       Impact factor: 2.472

Review 4.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment.

Authors:  Asher Brauner; Ofer Fridman; Orit Gefen; Nathalie Q Balaban
Journal:  Nat Rev Microbiol       Date:  2016-04       Impact factor: 60.633

5.  Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli.

Authors:  Tobias Dörr; Marin Vulić; Kim Lewis
Journal:  PLoS Biol       Date:  2010-02-23       Impact factor: 8.029

6.  Persister cells and tolerance to antimicrobials.

Authors:  Iris Keren; Niilo Kaldalu; Amy Spoering; Yipeng Wang; Kim Lewis
Journal:  FEMS Microbiol Lett       Date:  2004-01-15       Impact factor: 2.742

7.  Inhibitors of RecA activity discovered by high-throughput screening: cell-permeable small molecules attenuate the SOS response in Escherichia coli.

Authors:  Tim J Wigle; Jonathan Z Sexton; Anna V Gromova; Mallinath B Hadimani; Mark A Hughes; Ginger R Smith; Li-An Yeh; Scott F Singleton
Journal:  J Biomol Screen       Date:  2009-08-12

8.  Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe.

Authors:  Mike Sharland; Celine Pulcini; Stephan Harbarth; Mei Zeng; Sumanth Gandra; Shrey Mathur; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-20       Impact factor: 25.071

9.  Enhanced Efflux Activity Facilitates Drug Tolerance in Dormant Bacterial Cells.

Authors:  Yingying Pu; Zhilun Zhao; Yingxing Li; Jin Zou; Qi Ma; Yanna Zhao; Yuehua Ke; Yun Zhu; Huiyi Chen; Matthew A B Baker; Hao Ge; Yujie Sun; Xiaoliang Sunney Xie; Fan Bai
Journal:  Mol Cell       Date:  2016-04-21       Impact factor: 17.970

10.  Nutrient transitions are a source of persisters in Escherichia coli biofilms.

Authors:  Stephanie M Amato; Mark P Brynildsen
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more
  29 in total

1.  Metabolites Potentiate Nitrofurans in Nongrowing Escherichia coli.

Authors:  Sandra J Aedo; Juechun Tang; Mark P Brynildsen
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 2.  Biology of antimicrobial resistance and approaches to combat it.

Authors:  Sarah M Schrader; Julien Vaubourgeix; Carl Nathan
Journal:  Sci Transl Med       Date:  2020-06-24       Impact factor: 17.956

3.  Counting Chromosomes in Individual Bacteria to Quantify Their Impacts on Persistence.

Authors:  Allison M Murawski; Katherine Rittenbach; Christina J DeCoste; Gary Laevsky; Mark P Brynildsen
Journal:  Methods Mol Biol       Date:  2021

Review 4.  In Vitro Studies of Persister Cells.

Authors:  Niilo Kaldalu; Vasili Hauryliuk; Kathryn Jane Turnbull; Agnese La Mensa; Marta Putrinš; Tanel Tenson
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-11       Impact factor: 11.056

5.  Optogenetic control of the lac operon for bacterial chemical and protein production.

Authors:  Samantha S Ip; César Carrasco-López; Makoto A Lalwani; Catherine Day; Evan M Zhao; Hinako Kawabe; José L Avalos
Journal:  Nat Chem Biol       Date:  2020-09-07       Impact factor: 15.040

6.  Elevated Expression of Toxin TisB Protects Persister Cells against Ciprofloxacin but Enhances Susceptibility to Mitomycin C.

Authors:  Daniel Edelmann; Florian H Leinberger; Nicole E Schmid; Markus Oberpaul; Till F Schäberle; Bork A Berghoff
Journal:  Microorganisms       Date:  2021-04-27

7.  Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection.

Authors:  Françoise Van Bambeke; Marta Putrinš; Ivana Kerkez; Paul M Tulkens; Tanel Tenson
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

8.  Ploidy is an important determinant of fluoroquinolone persister survival.

Authors:  Allison M Murawski; Mark P Brynildsen
Journal:  Curr Biol       Date:  2021-03-11       Impact factor: 10.900

9.  The AcrAB-TolC Efflux Pump Impacts Persistence and Resistance Development in Stationary-Phase Escherichia coli following Delafloxacin Treatment.

Authors:  Brandon A Byrd; Blesing Zenick; Maria C Rocha-Granados; Hanna E Englander; Patricia J Hare; Travis J LaGree; Angela M DeMarco; Wendy W K Mok
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 10.  Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?

Authors:  Hyun-Eui Park; Wonsik Lee; Min-Kyoung Shin; Sung Jae Shin
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.